+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Human Papillomavirus Minor Capsid Protein L2 - Pipeline Review, H1 2020

  • ID: 4911747
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 33 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • Papivax LLC
  • Pathovax LLC
  • MORE
Human Papillomavirus Minor Capsid Protein L2 - Pipeline Review, H1 2020

Summary

According to the recently published report 'Human Papillomavirus Minor Capsid Protein L2 - Pipeline Review, H1 2020'; Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Human Papillomavirus Minor Capsid Protein L2 (L2) - L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dyne in in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins.

The report 'Human Papillomavirus Minor Capsid Protein L2 - Pipeline Review, H1 2020' outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Human Papillomavirus Infections, Cervical Intraepithelial Neoplasia (CIN), Human Papillomavirus (HPV) Associated Cancer and Cervical Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)
  • The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • Papivax LLC
  • Pathovax LLC
  • MORE
  • Introduction
  • Report Coverage
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in Therapeutics Development
  • 2A Pharma AB
  • Papivax LLC
  • Pathovax LLC
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Drug Profiles
  • 2AP-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RGVax - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TA-CIN - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Dormant Products
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Discontinued Products
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by 2A Pharma AB, H1 2020
  • Pipeline by Papivax LLC, H1 2020
  • Pipeline by Pathovax LLC, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Route of Administration,, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 2A Pharma AB
  • Papivax LLC
  • Pathovax LLC
Note: Product cover images may vary from those shown
Adroll
adroll